Table II.
Demographic and clinical characteristics at diagnosis and status at end of follow-up.
| LPC, n=677 | |||||
|---|---|---|---|---|---|
|
|
|||||
| Characteristic | Non-high-risk, n=433 | High-risk, n=244 | LAPC, n=113 | Overall, n=790 | P-value, LPC vs. LAPC |
| Median age (range), years | 66.0 (44.0–83.0) | 71.0 (46.0–89.0) | 70.0 (42.0–85.0) | 68.0 (42.0–89.0) | 0.001 |
| Age group, years (%) | |||||
| <60 | 87 (20.1) | 23 (9.4) | 5 (4.4) | 115 (14.6) | 0.001 |
| 60–69 | 211 (48.7) | 87 (35.7) | 48 (42.5) | 346 (43.8) | |
| >=70 | 135 (31.2) | 134 (54.9) | 60 (53.1) | 329 (41.6) | |
| Stage, n (%) | |||||
| I | 125 (28.9) | 6 (2.5) | 0 (0) | 131 (16.6) | <0.001a |
| II | 207 (47.8) | 211 (86.5) | 0 (0) | 418 (52.9) | |
| III | 99 (22.9) | 26 (10.7) | 113 (100) | 238 (30.1) | |
| Unknown | 2 (0.5) | 1 (0.4) | 0 (0) | 3 (0.4) | |
| ECOG, n (%) | |||||
| 0–1 | 419 (96.8) | 230 (94.3) | 110 (97.3) | 759 (96.1) | 0.627a |
| 2–3 | 3 (0.7) | 4 (1.6) | 2 (1.8) | 9 (1.1) | |
| Unknown | 11 (2.5) | 10 (4.1) | 1 (0.9) | 22 (2.8) | |
| Status at end of follow-up, n (%) | - | ||||
| Dead | 11 (2.5) | 21 (8.6) | 9 (8.0) | 41 (5.2) | |
| With evidence of disease | 8 (1.8) | 16 (6.6) | 4 (3.5) | 28 (3.5) | |
| Without evidence of disease | 3 (0.70) | 5 (2.00) | 5 (4.40) | 13 (1.60) | |
| Alive | 422 (97.5) | 223 (91.4) | 104 (92.0) | 749 (94.8) | |
| With evidence of disease | 77 (17.80) | 39 (16.00) | 10 (8.80) | 126 (15.90) | |
| Without evidence of disease | 345 (79.70) | 184 (75.40) | 94 (83.20) | 623 (78.90) | |
a
Statistical test was performed excluding the ‘Unknown’ category. ECOG, Eastern Cooperative Oncology Group; LPC, localised prostate cancer; LAPC, locally advanced prostate cancer.